rFVIIa is an effective agent to treat refractory bleeding in von Willebrand disease patients and to treat or prevent bleeding in patients with alloantibodies or autoantibodies directed against von Willebrand factor [33]. The gene discussed is VWF; the disease is platelet-type von Willebrand disease.